Taurolidine 2% catheter locking to prevent CRBSI
Research type
Research Study
Full title
Taurolidine 2% catheter locking to prevent catheter related bloodstream infections in patients on home parenteral nutrition with a high infection risk and those with a new central venous access device : A double-blind multicenter randomized controlled trial under guidance of the Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN
IRAS ID
142104
Contact name
Farooq Rahman
Contact email
Sponsor organisation
University college London
Clinicaltrials.gov Identifier
Research summary
Patients who out of many reasons are not able to eat and digest food through the alimentary canal receive nutrition through a blood line(catheter).These catheters often become infected through the manipulation and can lead to blood poisoning. An episode of blood poisoning is very dangerous and stressful for the patients and can even lead to death. Additionally, treating blood poisoning is a large resource and financial burden for the healthcare system. This research aims to prove that these infections can largely be avoided through the use of an antibacterial solution TauroSept which is left in the catheter between uses compared to the current use of saline. Some patients have more infections than others and are considered high risk patients. High risk patients and new patients receiving a catheter for the first time in a gastroenterology clinic in London will be given either TauroSept or saline solution to inject into their catheters when they are not feeding. Both the patients and their doctors will not know which one they are using.Any infections among these patients will be diagnosed and recorded during one year as well as other side effects like obstruction, skin infections and patients’ concerns. After one year use we will analyze how many blood infections the patients have had due to their catheters in the two groups and how long it took from the beginning of use to get an infection to see if TauroSept or saline works better to prevent infections in catheters.TauroSept has already been registered as a medical device and is being sold. No serious adverse effects have been registered so far which means the patients receiving Taurosept will not be at any risk. TauroSept will be used exactly the same way the patients are using saline in order not to change any routines for the patients.
REC name
London - Riverside Research Ethics Committee
REC reference
14/LO/0443
Date of REC Opinion
22 May 2014
REC opinion
Further Information Favourable Opinion